Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016

Abstract Survival in multiple myeloma (MM) has developed favorably over the past decades for reasons that have been ascribed to new medications and treatment. However, development of survival over a long period and comparison to other hematopoietic neoplasms (HN) is less well known. Here we used Swe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kari Hemminki, Asta Försti, Markus Hansson
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/e9dbb698bf1d4a86a408ddf4ec0ea1a1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e9dbb698bf1d4a86a408ddf4ec0ea1a1
record_format	dspace
spelling	oai:doaj.org-article:e9dbb698bf1d4a86a408ddf4ec0ea1a12021-12-02T15:09:07ZIncidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 201610.1038/s41598-021-96804-82045-2322https://doaj.org/article/e9dbb698bf1d4a86a408ddf4ec0ea1a12021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96804-8https://doaj.org/toc/2045-2322Abstract Survival in multiple myeloma (MM) has developed favorably over the past decades for reasons that have been ascribed to new medications and treatment. However, development of survival over a long period and comparison to other hematopoietic neoplasms (HN) is less well known. Here we used Swedish cancer data from the Nordcan database, spanning a 50-year period from 1967 to 2016, and analyzed 1- and 5-year survival data. As a novel type of analysis we calculate the difference in survival between year 1 and 5 which indicates how well survival was maintained in the 4-year period following year 1 after diagnosis. The relative 1- and 5- year survival increased constantly; the 5-year survival graph for women was almost linear. The difference between 1- and 5-year survival revealed that the 5-year survival gain was entirely due to the improvement in 1-year survival, except for the last period. Survival improvement in all HNs exceeded that in MM. The linear 5-year survival increase for female MM patients suggests a contribution by many small improvements in the first year care rather than single major events. The future challenges are to push the gains past year 1 and to extend them to old patients.Kari HemminkiAsta FörstiMarkus HanssonNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Kari Hemminki Asta Försti Markus Hansson Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016
description	Abstract Survival in multiple myeloma (MM) has developed favorably over the past decades for reasons that have been ascribed to new medications and treatment. However, development of survival over a long period and comparison to other hematopoietic neoplasms (HN) is less well known. Here we used Swedish cancer data from the Nordcan database, spanning a 50-year period from 1967 to 2016, and analyzed 1- and 5-year survival data. As a novel type of analysis we calculate the difference in survival between year 1 and 5 which indicates how well survival was maintained in the 4-year period following year 1 after diagnosis. The relative 1- and 5- year survival increased constantly; the 5-year survival graph for women was almost linear. The difference between 1- and 5-year survival revealed that the 5-year survival gain was entirely due to the improvement in 1-year survival, except for the last period. Survival improvement in all HNs exceeded that in MM. The linear 5-year survival increase for female MM patients suggests a contribution by many small improvements in the first year care rather than single major events. The future challenges are to push the gains past year 1 and to extend them to old patients.
format	article
author	Kari Hemminki Asta Försti Markus Hansson
author_facet	Kari Hemminki Asta Försti Markus Hansson
author_sort	Kari Hemminki
title	Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016
title_short	Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016
title_full	Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016
title_fullStr	Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016
title_full_unstemmed	Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016
title_sort	incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in sweden up to year 2016
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/e9dbb698bf1d4a86a408ddf4ec0ea1a1
work_keys_str_mv	AT karihemminki incidencemortalityandsurvivalinmultiplemyelomacomparedtootherhematopoieticneoplasmsinswedenuptoyear2016 AT astaforsti incidencemortalityandsurvivalinmultiplemyelomacomparedtootherhematopoieticneoplasmsinswedenuptoyear2016 AT markushansson incidencemortalityandsurvivalinmultiplemyelomacomparedtootherhematopoieticneoplasmsinswedenuptoyear2016
_version_	1718387910923780096

Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016

Ejemplares similares